Viatris Inc. VTRS
17.83
0.41
2.35%
as of 25 Sep
- Market cap
- $20.0B
- P/E
- 0.0×
Follow VTRS
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Viatris Inc. (VTRS) P/E ratio
Viatris Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (September 2026) to 762× (February 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 228× | 3,322.99% |
| FY2022 | 6.7× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 670× | 1,562.77% |
| FY2018 | 40.3× | 22.44% |
| FY2017 | 32.9× | (23.43%) |
| FY2016 | 43.0× | 39.10% |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 762×
Ten-year median
23.9×
Current reading's percentile
32
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| HIMS Hims & Hers Health, Inc. compare | n/m |
| VTRS Viatris Inc. | n/m |
| ELAN Elanco Animal Health Incorporated compare | n/m |
| ZTS Zoetis Inc. compare | 11.7× |
| UTHR United Therapeutics Corporation compare | 15.7× |
| NBIX Neurocrine Biosciences, Inc. compare | 19.6× |
| HLN Haleon PLC Sponsored ADR compare | 20.6× |
| RDY Dr. Reddy's Laboratories Ltd compare | 30.8× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 62.2× |
| Drug Manufacturers Specialty & Generic industry median | 20.1× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on VTRS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement